Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer

Video

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the FDA approval of ribociclib (LEE011) for use in combination with letrozole as a frontline therapy for patients with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the FDA approval of ribociclib (LEE011) for use in combination with letrozole as a frontline therapy for patients with hormone-receptor (HR)—positive, HER2-negative advanced breast cancer.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Related Content
Robert W. Mutter, MD

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Matt Coffey, PhD, president, chief executive officer, Oncolytics Biotech

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024
Article
Karen Pinilla Alba, MD

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024
Article